News

Subsequent to this agreement, Easton has signed a Letter Of Intent / NDA and has entered into high level negotiations with a private company based out of British

AHF MCO was awarded a contract covering Regions 10 & 11 — Broward, Miami-Dade and Monroe Counties. The new AHF MCO contract came about in response to a

In the trial, RAS specific immune responses were induced in all six patients and no substantial TG01 related toxicity was observed in the patients. Oslo University Hospital professor

The data submitted in the NDA support the use of LDV/SOF in patients with genotype 1 hepatitis C virus (HCV) infection, with a treatment duration of eight or

MG01CI (Metadoxine extended-release) is intended for the treatment of cognitive dysfunctions, such as attention deficit hyperactivity disorder (ADHD) and Fragile X Syndrome. Principal investigator of the trial will

The Phase II TRIG-05 trial is assessing TI-001, an investigational, nasally-delivered oxytocin therapeutic currently being examined to determine its efficacy, tolerability, and safety in chronic migraine patients. Secondary

As part of the agreement, PBL will use its ligand design and screening capabilities to identify Mimetic affinity ligands with the ability to capture and purify the new

Beleodaq (belinostat) for Injection, a novel pan-HDAC inhibitor is intended for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (R/R PTCL). The FDA establishes review

The company is likely to conduct the Phase II study for CF102 in Israel, Europe and the US. This study is designed to assess the safety and efficacy